Because PCSK9 inhibitors have been licensed since 2015 in several territories, pharmacoepidemiologic studies of the consequences of PCSK9 inhibitor use versus other lipid‐lowering agents for AD risk could also be conducted with large samples of individuals in national or insurance‐based prescription registers, as could the follow‐up of AD risk differences among past participants in PCSK9 inhibitor trials. This evidence concerns the gene PCSK9 and Alzheimer disease.